HCT characteristics according to type of HCT
| Characteristic . | Allo-HCT (n =118) . | Auto-HCT (n =53) . |
|---|---|---|
| Time from CLL diagnosis to HCT, median (range), mo | 44 (4-303) | 46 (5-172) |
| Time from RS diagnosis to HCT, median (range), mo | 11 (1-213) | 11 (3-172) |
| DLBCL-RS disease status (at HCT) | ||
| CR | 40 (34) | 35 (66) |
| PR | 51 (43) | 15 (28) |
| Resistant | 20 (17) | 2 (4) |
| Unknown | 7 (6) | 1 (2) |
| CLL/SLL disease status (at HCT) | ||
| CR | 27 (23) | 19 (36) |
| PR | 39 (33) | 15 (28) |
| Stable/untreated | 13 (11) | 5 (9) |
| Progressive | 17 (14) | 5 (9) |
| Missing/not assessed | 22 (19) | 9 (17) |
| Conditioning regimen (allo-HCT only) | ||
| MAC | 27 (23) | N/A |
| NMA/RIC | 91 (77) | N/A |
| TBI-containing conditioning regimen | 44 (37) | 1 (2) |
| GVHD prophylaxis | ||
| CNI ± others (except PTCY) | 100 (85) | N/A |
| PTCY ± CNI ± MMF | 14 (12) | N/A |
| Others* | 3 (3) | N/A |
| Missing | 1 (1) | N/A |
| Received ATG/alemtuzumab | 28 (24) | N/A |
| Donor type | ||
| HLA-matched related donor | 27 (23) | N/A |
| HLA-mismatched related donor | 18 (15) | N/A |
| Matched unrelated donor (8/8) | 47 (40) | N/A |
| Mismatched unrelated donor (≤7/8) | 7 (6) | N/A |
| Unrelated donor, matching unknown | 9 (8) | N/A |
| Cord blood | 10 (9) | N/A |
| Graft source | ||
| Bone marrow | 8 (7) | 0 |
| Peripheral blood | 103 (87) | 53 (100) |
| Cord blood | 7 (6) | 0 |
| Year of transplant | ||
| 2007-2013 | 31 (26) | 13 (25) |
| 2014-2017 | 87 (74) | 40 (75) |
| Follow-up after HCT, median (range), mo | 48 (4-98) | 49 (3-75) |
| Characteristic . | Allo-HCT (n =118) . | Auto-HCT (n =53) . |
|---|---|---|
| Time from CLL diagnosis to HCT, median (range), mo | 44 (4-303) | 46 (5-172) |
| Time from RS diagnosis to HCT, median (range), mo | 11 (1-213) | 11 (3-172) |
| DLBCL-RS disease status (at HCT) | ||
| CR | 40 (34) | 35 (66) |
| PR | 51 (43) | 15 (28) |
| Resistant | 20 (17) | 2 (4) |
| Unknown | 7 (6) | 1 (2) |
| CLL/SLL disease status (at HCT) | ||
| CR | 27 (23) | 19 (36) |
| PR | 39 (33) | 15 (28) |
| Stable/untreated | 13 (11) | 5 (9) |
| Progressive | 17 (14) | 5 (9) |
| Missing/not assessed | 22 (19) | 9 (17) |
| Conditioning regimen (allo-HCT only) | ||
| MAC | 27 (23) | N/A |
| NMA/RIC | 91 (77) | N/A |
| TBI-containing conditioning regimen | 44 (37) | 1 (2) |
| GVHD prophylaxis | ||
| CNI ± others (except PTCY) | 100 (85) | N/A |
| PTCY ± CNI ± MMF | 14 (12) | N/A |
| Others* | 3 (3) | N/A |
| Missing | 1 (1) | N/A |
| Received ATG/alemtuzumab | 28 (24) | N/A |
| Donor type | ||
| HLA-matched related donor | 27 (23) | N/A |
| HLA-mismatched related donor | 18 (15) | N/A |
| Matched unrelated donor (8/8) | 47 (40) | N/A |
| Mismatched unrelated donor (≤7/8) | 7 (6) | N/A |
| Unrelated donor, matching unknown | 9 (8) | N/A |
| Cord blood | 10 (9) | N/A |
| Graft source | ||
| Bone marrow | 8 (7) | 0 |
| Peripheral blood | 103 (87) | 53 (100) |
| Cord blood | 7 (6) | 0 |
| Year of transplant | ||
| 2007-2013 | 31 (26) | 13 (25) |
| 2014-2017 | 87 (74) | 40 (75) |
| Follow-up after HCT, median (range), mo | 48 (4-98) | 49 (3-75) |
Unless otherwise noted, data are n (%).
ATG, anti-thymocyte globulin; CNI, calcineurin inhibitor; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; NMA, nonmyeloablative conditioning; PR, partial response; PTCY, posttransplant cyclophosphamide; RIC, reduced-intensity conditioning; TBI, total body irradiation; ±, with or without.
CD34 selection (n =1), ex vivo T-cell depletion (n =1), sirolimus (n =1).